Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development

Journal of Neuroimmune Pharmacology

Volumn 5, Issue 2, 2010, Pages 220-230

  Kap, Yolanda S ^a,b   Laman, Jon D ^b   ‘t Hart, Bert A ^a,b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

B cells; CD40; IL 12; IL 23; NK CTL; Non human primate

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CHIMERIC ANTIBODY; FREUND ADJUVANT; INTERLEUKIN 12P40; INTERLEUKIN 23; MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RITUXIMAB; USTEKINUMAB;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BRAIN REGION; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GRAY MATTER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MACACA; MARMOSET; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVOUS SYSTEM INFLAMMATION; NERVOUS SYSTEM INJURY; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHESUS MONKEY; RODENT; T LYMPHOCYTE;

EID: 77954564262     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-009-9178-y     Document Type: Review

References (67)

1. Barnett MH, Parratt JD, Cho ES, Prineas JW (2009) Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 65:32-46
2. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Wurfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101:8705-8708
3. Blezer EL, Bauer J, Brok HP, Nicolay K, t Hart BA (2007) Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis. NMR Biomed 20:90-103
4. Bo L, Geurts JJ,Mork SJ, van der Valk P (2006)Greymatter pathology in multiple sclerosis. Acta Neurol Scand Suppl 183:48-50
5. Boon L, Brok HP, Bauer J, Ortiz-Buijsse A, Schellekens MM, Ramdien-Murli S, Blezer E, van Meurs M, Ceuppens J, de Boer M, t Hart BA, Laman JD (2001) Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 167:2942-2949
6. Brok HP, Uccelli A, Kerlero De Rosbo N, Bontrop RE, Roccatagliata L, de Groot NG, Capello E, Laman JD, Nicolay K, Mancardi GL, Ben-Nun A, Hart BA (2000) Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J Immunol 165:1093-1101
7. Brok HP, van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, Laman JD, Bauer J, t Hart BA (2002) Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 169:6554-6563
8. Brok HP, Boven L, van Meurs M, Kerlero de Rosbo N, Celebi-Paul L, Kap YS, Jagessar A, Hintzen RQ, Keir G, Bajramovic J, Ben-Nun A, Bauer J, Laman JD, Amor S, t Hart BA (2007) The human CMV-UL86 peptide 981-1003 shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 34-56, but lacks the capacity to induce EAE in rhesus monkeys. J Neuroimmunol 182:135-152
9. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786-1801
10. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502-1517
11. Cross AH, Lyons JA, San M, Keeling RM, Ku G, Racke MK (1999) T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis. Eur J Immunol 29:3140-3147
12. Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L (2006) The value of animal models for drug development in multiple sclerosis. Brain 129:1940-1952
13. Gausas J, Paterson PY, Day ED, Dal Canto MC (1982) Intact B-cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats. Cell Immunol 72:360-366
14. Genain CP, Hauser SL (2001) Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol Rev 183:159-172
15. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, Lees MB, Linington C, Hauser SL (1995) Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96:2966-2974
16. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 93:2499-2504
17. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971
18. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688 (Pubitemid 351240747)
19. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH (2008) T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125:161-169
20. Hjelmstrom P, Juedes AE, Fjell J, Ruddle NH (1998) B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol 161:4480-4483
21. Jagessar SA, Smith PA, Blezer E, Delarasse C, Pham-Dinh D, Laman JD, Bauer J, Amor S, t Hart B (2008) Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets. J Neuropathol Exp Neurol 67:326-340
22. Kap YS, Smith P, Jagessar SA, Remarque E, Blezer E, Strijkers GJ, Laman JD, Hintzen RQ, Bauer J, Brok HP, t Hart BA (2008) Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells. J Immunol 180:1326- 1337
23. Kappos L, Antel J, Comi G, Montalban X, OConnor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140
24. Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL (2005) Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohns disease. Aliment Pharmacol Ther 22:111-122
25. Kleinschnitz C, Meuth SG, Wiendl H (2008) The trials and errors in MS therapy. Int MS J 15:79-90
26. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715
27. Krishnamoorthy G, Holz A, Wekerle H (2007) Experimental models of spontaneous autoimmune disease in the central nervous system. J Mol Med 85:1161-1173
28. Kroenke MA, Segal BM (2007) Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J Neurosci Res 85:1685-1693
29. Laman JD, Claassen E, Noelle RJ (1996) Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 16:59-108
30. Laman JD, t Hart BA, Brok H, Meurs M, Schellekens MM, Kasran A, Boon L, Bauer J, Boer M, Ceuppens J (2002) Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 32:2218- 2228
31. Lassmann H, Ransohoff RM (2004) The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol 25:132-137
32. Longbrake EE, RackeMK(2009)Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 9:319-321
33. Lopez-Diego RS, Weiner HL (2008) Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 7:909-925
34. Lunemann JD, Munz C (2009) EBV in MS: guilty by association? Trends Immunol 30:243-248
35. Mancardi G, t Hart B, Roccatagliata L, Brok H, Giunti D, Bontrop R, Massacesi L, Capello E, Uccelli A (2001) Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J Neurol Sci 184:41-49
36. Massacesi L, Genain CP, Lee-Parritz D, Letvin NL, Canfield D, Hauser SL (1995) Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. Ann Neurol 37:519-530
37. McFarland HI, Lobito AA, Johnson MM, Nyswaner JT, Frank JA, Palardy GR, Tresser N, Genain CP, Mueller JP, Matis LA, Lenardo MJ (1999) Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J Immunol 162:2384-2390
38. Merkler D, Boscke R, Schmelting B, Czeh B, Fuchs E, Bruck W, Stadelmann C (2006a) Differentialmacrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol 16:117-123
39. Merkler D, Schmelting B, Czeh B, Fuchs E, Stadelmann C, Bruck W (2006b) Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 12:369-374
40. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731-2738
41. Polman CH, OConnor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
42. Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM (2005) Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 128:2713-2721
43. Pomeroy IM, Jordan EK, Frank JA, Matthews PM, Esiri MM (2008) Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci Lett 437:121-124
44. Ransohoff RM (2006) EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol 27:167-168
45. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F (2009) C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10:514-523
46. Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, Pedotti R, DiGennaro CD,Mitchell DJ, Fong D, Ho PP, Ruiz PJ,Maverakis E, Stevens DB, Bernard CC, Martin R, Kuchroo VK, van Noort JM, Genain CP, Amor S, Olsson T, Utz PJ, Garren H, Steinman L (2003) Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 21:1033-1039
47. Schafer S, Kolkhof P (2008) Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 13:913-916
48. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH (2008) Repeated subcutaneous injections of IL12/ 23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7:796-804
49. Sekiguchi Y, Ichikawa M, Takamoto M, Ota H, Koh CS, Muramatsu M, Honjo T, Agematsu K (2009) Antibodies to myelin oligodendrocyte glycoprotein are not involved in the severity of chronic non-remitting experimental autoimmune encephalomyelitis. Immunol Lett 122:145-149
50. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F (2007) Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899-2912
51. Sriram S, Steiner I (2005) Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58:939-945
52. Steinman L, Zamvil SS (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12-21
53. t Hart BA, Amor S (2003) The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. Curr Opin Neurol 16:375383
54. t Hart BA, Massacesi L (2009) Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol 68:341355
55. t Hart BA, Bauer J, Muller HJ, Melchers B, Nicolay K, Brok H, Bontrop RE, Lassmann H, Massacesi L (1998) Histopathological characterization of magnetic resonance imaging detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 153:649663
56. t Hart BA, Laman JD, Bauer J, Blezer E, van Kooyk Y, Hintzen RQ (2004) Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 3:588597
57. t Hart BA, Bauer J, Brok HP, Amor S (2005a) Non-human primate models of experimental autoimmune encephalomyelitis: variations on a theme. J Neuroimmunol 168:112
58. t Hart BA, Blezer EL, Brok HP, Boon L, de Boer M, Bauer J, Laman JD (2005b) Treatment with chimeric anti human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 163:3139
59. t Hart BA, Smith P, Amor S, Strijkers GJ, Blezer EL (2006) MRIguided immunotherapy development for multiple sclerosis in a primate. Drug Discov Today 11:5866
60. t Hart BA, Jagessar A, Kap YS, Brok HPM (2007) Preclinical models of multiple sclerosis in nonhuman primates. Expert Rev Clin Immunol 3:749761
61. t Hart BA, Hintzen RQ, Laman JD (2008) Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis 5:3852
62. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Drager AM, Ader HJ, van Houwelingen JC, Barkhof F, Polman CH, Nagelkerken L (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 45:695-703
63. Van der Aa A, Hellings N, Bernard CC, Raus J, Stinissen P (2003) Functional properties of myelin oligodendrocyte glycoproteinreactive T cells in multiple sclerosis patients and controls. J Neuroimmunol 137:164-176
64. van Kooten C, Banchereau J (1997) Functional role of CD40 and its ligand. Int Arch Allergy Immunol 113:393-399
65. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608 (Pubitemid 38625664)
66. von Herrath MG, Nepom GT (2005) Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J Exp Med 202:1159-1162
67. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Almendinger SE, Blewett MM, Bruck W, Hafler DA, OConnor KC (2009) Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain (in press)